We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 186,038 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
From Apr 2019 to Apr 2024
TIDMSBTX
RNS Number : 7619S
SkinBioTherapeutics PLC
18 March 2021
SkinBioTherapeutics plc
Significant Shareholder
Manchester, UK - 18 March 2021 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, provides an update on the shareholding of OptiBiotix Health Plc ("OptiBiotix") in the Company.
As part of the Placing and Open Offer announced 30 October 2020, the Company, OptiBiotix and Cenkos Securities plc ("Cenkos"), entered into a lock-in and orderly market agreement pursuant to which OptiBiotix agreed to certain undertakings. On 12 March 2021 OptiBiotix approached the Company and Cenkos seeking consent to sell two million shares in the Company. Noting the high demand for SBTX shares, the Company and Cenkos consented to the sale of the shares subject to maintaining an orderly market.
Consequent to the disposal of shares, OptiBiotix's holding in the Company has reduced to 36,138,569 shares representing 23.2% of the issued share capital.
All parties are committed to maintaining the terms of the lock-in agreement for the remainder of its term and there is no expectation that a further consent request will be made by or granted to OptiBiotix.
TR-1: S tandard form for notification of major holdings
Hot Features
Premium
1a. Identity of the issuer or the SkinBioTherapeutics plc
underlying issuer of existing shares Company No: 09632164 (England)
to which voting rights are attached
(ii) :
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
------------------
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
------------------
An acquisition or disposal of financial instruments
------------------
An event changing the breakdown of voting rights
------------------
Other (please specify)(iii) :
------------------
3. Details of person subject to the notification obligation (iv)
Name Optibiotix Health PLC
City and country of registered office York (UK)
(if applicable)
4. Full name of shareholder(s) (if different from 3.) (v)
Name
---------------------------------------------------------
City and country of registered office
(if applicable)
---------------------------------------------------------
5. Date on which the threshold was 17 March 2021
crossed or reached (vi) :
---------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 18 March 2021
---------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
----------------------- ------------------- ---------------- ------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 23.18 23.18 155,889,922
----------------------- ------------------- ---------------- ------------------
Position of
previous notification
(if
applicable) 24.46 24.46
----------------------- ------------------- ---------------- ------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
---------------------
Ordinary 36,138,569 23.18
-------------------- --------------------- ---------------------------------- ---------------------
SUBTOTAL 8. A 36,138,569 23.18
------------------------------------------- ---------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument (x) (xi) be acquired if
the instrument
is
exercised/converted.
-------------------- --------------------- ---------------------------------- ---------------------
SUBTOTAL 8. B 1
--------------------- ---------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date (x) Conversion cash voting rights rights
instrument Period (xi) settlement
(xii)
--------------------- --------------------- --------------- -----------------
SUBTOTAL 8.B.2
--------------- -----------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled X
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer (xiii)
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (xiv) (please add additional
rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
-------------------------------- ------------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
---------------------------------------------------
The number and % of voting rights
held
---------------------------------------------------
The date until which the voting rights
will be held
---------------------------------------------------
11. Additional information (xvi)
Change due to sale of shares
Place of completion Edinburgh
Date of completion 18 March 2021
--------------
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 Stuart J . Ashman, CEO 468 2760 Doug Quinn, CFO Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 & Broker) 7397 8900 Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales) Instinctif Partners Tel: +44 (0) 20 Melanie Toyne-Sewell / Phillip Marriage 7457 2020 / Nathan Billis SkinBio@instinctif.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLJPMITMTMBBBB
(END) Dow Jones Newswires
March 18, 2021 10:02 ET (14:02 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
